biostudies-literatureUnknown37(6)Lee SKMinistry of Education<h4>Background/aims</h4>To evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting.<h4>Methods</h4>A total of 273 patients who received LDV/SOF therapy between May 2016 and February 2021 were consecutively enrolled and analyzed. A per-protocol analysis was performed to evaluate the virologic response.<h4>Results</h4>Seventy-five percent were infected with genotype 1, and 25% were infected with genotype 2. A hundred eightyone (66.3%) patients had chronic hepatitis, 74 (27.1%) had compensated cirrhosis, eight (2.9%) had decompensated cirrhosis, and 10 (3.7%) had undergone liver transplantation. Undetectable HCV RNA at week 4 was achieved in 90.2% (231/256) of patients, 99.2% (250/252) achieved The Korean journal of internal medicine1167-1175https://www.ebi.ac.uk/biostudies/studies/S-EPMC9666263biostudies-literatureReal-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.PMC9666263Yang HYoon SKKwon JHSung PSLee SKSong MJChang UINam SWLee JBae SHYang JMJang JWKim CWYoo SHKim SHLee HLChoi JYLee SWSong DSKim HYNam HHan JWfalseReal-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.<h4>Background/aims</h4>To evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting.<h4>Methods</h4>A total of 273 patients who received LDV/SOF therapy between May 2016 and February 2021 were consecutively enrolled and analyzed. A per-protocol analysis was performed to evaluate the virologic response.<h4>Results</h4>Seventy-five percent were infected with genotype 1, and 25% were infected with genotype 2. A hundred eightyone (66.3%) patients had chronic hepatitis, 74 (27.1%) had compensated cirrhosis, eight (2.9%) had decompensated cirrhosis, and 10 (3.7%) had undergone liver transplantation. Undetectable HCV RNA at week 4 was achieved in 90.2% (231/256) of patients, 99.2% (250/252) achieved 2022-01-01T00:00:00Z2022 Nov2025-04-21T16:09:46.652Z2025-04-21T16:09:46.652ZS-EPMC96662633561830210.3904/kjim.2022.013